样式: 排序: IF: - GO 导出 标记为已读
-
The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-16 Ophélie Le Chapelain, Soumaya Jadoui, Angèle Gros, Samir Barbaria, Keltouma Benmeziane, Véronique Ollivier, Sébastien Dupont, Mialitiana Solo Nomenjanahary, Sabrina Mavouna, Jasmina Rogozarski, Marie-Anne Mawhin, Giuseppina Caligiuri, Sandrine Delbosc, Françoise Porteu, Bernhard Nieswandt, Pierre H Mangin, Yacine Boulaftali, Benoit Ho-Tin-Noé
How platelets interact with and influence the tumor microenvironment (TME) remains poorly characterized. We compared the presence and participation of platelets in the TME of two tumors characterized by highly different TME, PyMT AT-3 mammary tumors and B16F1 melanoma. We show that whereas firmly adherent platelets continuously line tumor vessels of both AT-3 and B16F1 tumors, abundant extravascular
-
Gli1-mediated tumor cell-derived bFGF promotes tumor angiogenesis and pericyte coverage in non-small cell lung cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-16 Xueping Lei, Zhan Li, Manting Huang, Lijuan Huang, Yong Huang, Sha Lv, Weisong Zhang, Zhuowen Chen, Yuanyu Ke, Songpei Li, Jingfei Chen, Xiangyu Yang, Qiudi Deng, Junshan Liu, Xiyong Yu
Tumor angiogenesis inhibitors have been applied for non-small cell lung cancer (NSCLC) therapy. However, the drug resistance hinders their further development. Intercellular crosstalk between lung cancer cells and vascular cells was crucial for anti-angiogenenic resistance (AAD). However, the understanding of this crosstalk is still rudimentary. Our previous study showed that Glioma-associated oncogene
-
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-16 Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue
The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges. To date, analyses of tumor biopsies are the only parameter used to guide prognosis to ICI therapy. Tumor biopsies, however, are often difficult to obtain and tissue-based
-
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-15 Diego de Miguel‑Perez, Murat Ak, Priyadarshini Mamindla, Alessandro Russo, Serafettin Zenkin, Nursima Ak, Vishal Peddagangireddy, Luis Lara‑Mejia, Muthukumar Gunasekaran, Andres F. Cardona, Aung Naing, Fred R. Hirsch, Oscar Arrieta, Rivka R. Colen, Christian Rolfo
Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable predictive biomarkers. We showed preliminary data on the predictive role of the combination of radiomics and plasma extracellular vesicle (EV) PD-L1 to predict durable response
-
Correction: RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-14 Yu-Jiao Zhou, Min-Li Yang, Xin He, Hui-Ying Gu, Ji-Hua Ren, Sheng-Tao Cheng, Zhou Fu, Zhen-Zhen Zhang, Juan Chen
Correction: J Exp Clin Cancer Res 43, 45 (2024) https://doi.org/10.1186/s13046-023-02929-1 Following publication of the original article [1], errors were spotted particularly in Fig. 6, specifically: Fig. 6b – upper panels, incorrect representative image used for migration transwell assays of Huh7 cells transfected with EV Fig. 6d – lower panels, incorrect representative image used for invasion transwell
-
C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-13 Mengbao Du, Mowang Wang, Meng Liu, Shan Fu, Yu Lin, Yankun Huo, Jian Yu, Xiaohong Yu, Chong Wang, Haowen Xiao, Limengmeng Wang
Acute myeloid leukemia (AML) with biallelic (CEBPAbi) as well as single mutations located in the bZIP region is associated with a favorable prognosis, but the underlying mechanisms are still unclear. Here, we propose that two isoforms of C/EBPα regulate DNA damage-inducible transcript 3 (DDIT3) transcription in AML cells corporately, leading to altered susceptibility to endoplasmic reticulum (ER) stress
-
Functionally-instructed modifiers of response to ATR inhibition in experimental glioma J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-12 Bianca Walter, Sophie Hirsch, Laurence Kuhlburger, Aaron Stahl, Leonard Schnabel, Silas Wisser, Lara A. Haeusser, Foteini Tsiami, Sarah Plöger, Narges Aghaallaei, Advaita M Dick, Julia Skokowa, Christian Schmees, Markus Templin, Katja Schenke-Layland, Marcos Tatagiba, Sven Nahnsen, Daniel J. Merk, Ghazaleh Tabatabai
The DNA damage response (DDR) is a physiological network preventing malignant transformation, e.g. by halting cell cycle progression upon DNA damage detection and promoting DNA repair. Glioblastoma are incurable primary tumors of the nervous system and DDR dysregulation contributes to acquired treatment resistance. Therefore, DDR targeting is a promising therapeutic anti-glioma strategy. Here, we investigated
-
Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-12 Fan Yang, Chenyang Yuan, Fanghui Chen, Zhaohui S. Qin, Nicole C. Schmitt, Gregory B. Lesinski, Nabil F. Saba, Yong Teng
While T cell-activating immunotherapies against recurrent head and neck squamous cell carcinoma (HNSCC) have shown impressive results in clinical trials, they are often ineffective in the majority of patients. NK cells are potential targets for immunotherapeutic intervention; however, the setback in monalizumab-based therapy in HNSCC highlights the need for an alternative treatment to enhance their
-
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-09 Sara Iachettini, Irene Terrenato, Manuela Porru, Serena Di Vito, Angela Rizzo, Carmen D’Angelo, Eleonora Petti, Roberto Dinami, Carmen Maresca, Anna Di Benedetto, Aldo Palange, Antonino Mulè, Angela Santoro, Antonella Palazzo, Paola Fuso, Antonella Stoppacciaro, Patrizia Vici, Lorena Filomeno, Francesca Sofia Di Lisa, Teresa Arcuri, Eriseld Krasniqi, Alessandra Fabi, Annamaria Biroccio, Pasquale Zizza
Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC form – is refractory to endocrine and most of the target therapies. In this view, taxane-based therapy still represents the elective strategy for the treatment of this tumor. However, due variability
-
A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-08 Bolin Wang, Jinli Pei, Shengnan Xu, Jie Liu, Jinming Yu
Glutamine metabolism plays a pivotal role in cancer progression, immune cell function, and the modulation of the tumor microenvironment. Dysregulated glutamine metabolism has been implicated in cancer development and immune responses, supported by mounting evidence. Cancer cells heavily rely on glutamine as a critical nutrient for survival and proliferation, while immune cells require glutamine for
-
TGF-β-activated circRYK drives glioblastoma progression by increasing VLDLR mRNA expression and stability in a ceRNA- and RBP-dependent manner J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-08 Yuhang Wang, Binbin Wang, Wenping Cao, Xiupeng Xu
The TGF-β signalling pathway is intricately associated with the progression of glioblastoma (GBM). The objective of this study was to examine the role of circRNAs in the TGF-β signalling pathway. In our research, we used transcriptome analysis to search for circRNAs that were activated by TGF-β. After confirming the expression pattern of the selected circRYK, we carried out in vitro and in vivo cell
-
S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-08 Xiaoxuan Tu, Longxian Chen, Yi Zheng, Chenglin Mu, Zhiwei Zhang, Feiyu Wang, Yiqing Ren, Yingxin Duan, Hangyu Zhang, Zhou Tong, Lulu Liu, Xunqi Sun, Peng Zhao, Lie Wang, Xinhua Feng, Weijia Fang, Xia Liu
The paucity of reliable biomarkers for predicting immunotherapy efficacy in patients with advanced hepatocellular carcinoma (HCC) has emerged as a burgeoning concern with the expanding use of immunotherapy. This study endeavors to delve into the potential peripheral biomarkers capable of prognosticating efficacy in HCC patients who are poised to receive anti-PD-1 monotherapy within the phase III clinical
-
Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1α) in human cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-08 Peng Chen, Amit Sharma, Hans Weiher, Ingo G.H. Schmidt-Wolf
A firm link between endoplasmic reticulum (ER) stress and tumors has been wildly reported. Endoplasmic reticulum oxidoreductase 1 alpha (ERO1α), an ER-resident thiol oxidoreductase, is confirmed to be highly upregulated in various cancer types and associated with a significantly worse prognosis. Of importance, under ER stress, the functional interplay of ERO1α/PDI axis plays a pivotal role to orchestrate
-
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-06 Yun Hu, Alexey Revenko, Hampartsoum Barsoumian, Genevieve Bertolet, Natalie Wall Fowlkes, Hadi Maazi, Morgan Maureen Green, Kewen He, Duygu Sezen, Tiffany A. Voss, Claudia S Kettlun Leyton, Fatemeh Masrorpour, Zahid Rafiq, Nahum Puebla-Osorio, Carola Leuschner, Robert MacLeod, Maria Angelica Cortez, James W. Welsh
The combination of radiotherapy and immunotherapy (immunoradiotherapy) has been increasingly used for treating a wide range of cancers. However, some tumors are resistant to immunoradiotherapy. We have previously shown that MER proto-oncogene tyrosine kinase (MerTK) expressed on macrophages mediates resistance to immunoradiotherapy. We therefore sought to develop therapeutics that can mitigate the
-
KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-05 Hongshi Cai, Jianfeng Liang, Yaoqi Jiang, Ziyi Wang, Hongyu Li, Wenjin Wang, Cheng Wang, Jinsong Hou
Head and neck squamous carcinoma (HNSCC) is known for its high aggressiveness and susceptibility to cervical lymph node metastasis, which greatly contributes to its poor prognosis. During tumorigenesis, many types of cancer cells acquire oncogenic super-enhancers (SEs) that drive the overexpression of oncogenes, thereby maintaining malignant progression. This study aimed to identify and validate the
-
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-05 Xiaobin Wang, Yingqing Shi, Hua Shi, Xiaoyu Liu, Aijun Liao, Zhuogang Liu, Robert Z. Orlowski, Rui Zhang, Huihan Wang
Proteasome inhibitors (PIs) are one of the most important classes of drugs for the treatment of multiple myeloma (MM). However, almost all patients with MM develop PI resistance, resulting in therapeutic failure. Therefore, the mechanisms underlying PI resistance in MM require further investigation. We used several MM cell lines to establish PI-resistant MM cell lines. We performed RNA microarray and
-
Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-01 Bisheng Cheng, Lingfeng Li, Tianlong Luo, Qiong Wang, Yong Luo, Shoumin Bai, Kaiwen Li, Yiming Lai, Hai Huang
Docetaxel resistance represents a significant obstacle in the treatment of prostate cancer. The intricate interplay between cytokine signalling pathways and transcriptional control mechanisms in cancer cells contributes to chemotherapeutic resistance, yet the underlying molecular determinants remain only partially understood. This study elucidated a novel resistance mechanism mediated by the autocrine
-
GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-01 M Caforio, S Iacovelli, C Quintarelli, F Locatelli, Valentina Folgiero
CRISPR/Cas9 system to treat human-related diseases has achieved significant results and, even if its potential application in cancer research is improving, the application of this approach in clinical practice is still a nascent technology. CRISPR/Cas9 technology is not yet used as a single therapy to treat tumors but it can be combined with traditional treatment strategies to provide personalized
-
Tight junction protein cingulin variant is associated with cancer susceptibility by overexpressed IQGAP1 and Rac1-dependent epithelial-mesenchymal transition J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-01 Yi-Ting Huang, Ya-Ting Hsu, Pei-Ying Wu, Yu-Min Yeh, Peng-Chan Lin, Keng-Fu Hsu, Meng-Ru Shen
Cingulin (CGN) is a pivotal cytoskeletal adaptor protein located at tight junctions. This study investigates the link between CGN mutation and increased cancer susceptibility through genetic and mechanistic analyses and proposes a potential targeted therapeutic approach. In a high-cancer-density family without known pathogenic variants, we performed tumor-targeted and germline whole-genome sequencing
-
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-03-01 Kathryn A. F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang-Yu Lian, Sara S. F. Al-Badran, Jean A. Quinn, Assya Legrini, Jitwadee Inthagard, Peter G. Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A. Gillespie, Megan Mills, Aula Ammar, Jennifer Hay, Ditte Andersen, Colin Nixon, Selma Rebus, David K. Chang, Caroline Kelly, Andrea Harkin, Janet Graham, David Church, Ian Tomlinson
Colorectal cancer (CRC) is a heterogenous malignancy underpinned by dysregulation of cellular signaling pathways. Previous literature has implicated aberrant JAK/STAT3 signal transduction in the development and progression of solid tumors. In this study we investigate the effectiveness of inhibiting JAK/STAT3 in diverse CRC models, establish in which contexts high pathway expression is prognostic and
-
IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-29 Zhengyang Hu, Qihai Sui, Xing Jin, Guangyao Shan, Yiwei Huang, Yanjun Yi, Dejun Zeng, Mengnan Zhao, Cheng Zhan, Qun Wang, Zongwu Lin, Tao Lu, Zhencong Chen
Lung cancer is one of the most common tumors in the world, and metastasis is one of the major causes of tumor-related death in lung cancer patients. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment (TME) and are frequently associated with tumor metastasis in human cancers. However, the regulatory mechanisms of TAMs in lung cancer metastasis remain unclear. Single-cell
-
ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-29 Tao-Yan Lin, Jun-Shuang Jia, Wei-Ren Luo, Xiao-Lin Lin, Sheng-Jun Xiao, Jie Yang, Jia-Wei Xia, Chen Zhou, Zhi-Hao Zhou, Shu-Jun Lin, Qi-Wen Li, Zhi-Zhi Yang, Ye Lei, Wen-Qing Yang, Hong-Fen Shen, Shi-Hao Huang, Sheng-Chun Wang, Lin-Bei Chen, Yu-Lin Yang, Shu-Wen Xue, Yong-Long Li, Guan-Qi Dai, Ying Zhou, Ying-Chun Li, Fang Wei, Xiao-Xiang Rong, Xiao-Jun Luo, Bing-Xia Zhao, Wen-Hua Huang, Dong Xiao
In recent years, the development of adjunctive therapeutic hyperthermia for cancer therapy has received considerable attention. However, the mechanisms underlying hyperthermia resistance are still poorly understood. In this study, we investigated the roles of cold‑inducible RNA binding protein (Cirbp) in regulating hyperthermia resistance and underlying mechanisms in nasopharyngeal carcinoma (NPC)
-
Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-27 Lidwien P. Smabers, Emerens Wensink, Carla S. Verissimo, Esmee Koedoot, Katerina-Chara Pitsa, Maarten A. Huismans, Celia Higuera Barón, Mayke Doorn, Liselot B. Valkenburg-van Iersel, Geert A. Cirkel, Anneta Brousali, René Overmeer, Miriam Koopman, Manon N. Braat, Bas Penning de Vries, Sjoerd G. Elias, Robert G. Vries, Onno Kranenburg, Sylvia F. Boj, Jeanine M. Roodhart
The inability to predict treatment response of colorectal cancer patients results in unnecessary toxicity, decreased efficacy and survival. Response testing on patient-derived organoids (PDOs) is a promising biomarker for treatment efficacy. The aim of this study is to optimize PDO drug screening methods for correlation with patient response and explore the potential to predict responses to standard
-
Targeting HDAC6 improves anti-CD47 immunotherapy J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-27 Maria Gracia-Hernandez, Ashutosh S. Yende, Nithya Gajendran, Zubaydah Alahmadi, Xintang Li, Zuleima Munoz, Karen Tan, Satish Noonepalle, Maho Shibata, Alejandro Villagra
Cancer cells can overexpress CD47, an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells. Several clinical trials have reported that CD47 blockade reduces tumor growth in hematological malignancies. However, CD47 blockade has shown modest results in solid tumors, including melanoma. Our group
-
Tumor-derived exosomal ADAM17 promotes pre-metastatic niche formation by enhancing vascular permeability in colorectal cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-27 Keyu Li, Wenhua Xue, Zhihua Lu, Suo Wang, Jiayao Zheng, Kuangyi Lu, Ming Li, Yang Zong, Feng Xu, Jiamin Dai, Yang Yang, Jinbing Sun
Hematological metastasis has been recognized as a crucial factor contributing to the high rates of metastasis and mortality observed in colorectal cancer (CRC). Notably, exosomes derived from cancer cells participate in the formation of CRC pre-metastatic niches; however, the mechanisms underlying their effects are largely unknown. While our preliminary research revealed the role of exosome-derived
-
Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-27 Chiara Naro, Ambra Antonioni, Vanessa Medici, Cinzia Caggiano, Ariane Jolly, Pierre de la Grange, Pamela Bielli, Maria Paola Paronetto, Claudio Sette
Advanced prostate cancer (PC) is characterized by insensitivity to androgen deprivation therapy and chemotherapy, resulting in poor outcome for most patients. Thus, advanced PC urgently needs novel therapeutic strategies. Mounting evidence points to splicing dysregulation as a hallmark of advanced PC. Moreover, pharmacologic inhibition of the splicing process is emerging as a promising option for this
-
Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-26 Sandra Muñoz-Galván, Eva M. Verdugo-Sivianes, José M. Santos-Pereira, Purificación Estevez-García, Amancio Carnero
Hypoxia in solid tumors is an important source of chemoresistance that can determine poor patient prognosis. Such chemoresistance relies on the presence of cancer stem cells (CSCs), and hypoxia promotes their generation through transcriptional activation by HIF transcription factors. We used ovarian cancer (OC) cell lines, xenograft models, OC patient samples, transcriptional databases, induced pluripotent
-
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-26 Weisong Li, Kai Zhang, Wenjun Wang, Yuanyuan Liu, Jianming Huang, Meihong Zheng, Ling Li, Xinyu Zhang, Minjuan Xu, Guofang Chen, Liefeng Wang, Shuyong Zhang
Ovarian cancer (OC) is a prevalent malignancy in the female reproductive system, and developing effective targeted therapies for this disease remains challenging. The aim of this study was to use clinically-relevant OC models to evaluate the therapeutic effectiveness of RC48, an antibody-drug conjugate (ADC) targeting HER2, either alone or in combination with the VEGFR inhibitor Cediranib Maleate (CM)
-
Correction: CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-23 Wenwei Liao, Jinpeng Du, Lian Li, Xianquan Wu, Xing Chen, Qingbo Feng, Lin Xu, Xiangzheng Chen, Mingheng Liao, Jiwei Huang, Kefei Yuan, Yong Zeng
Correction: J Exp Clin Cancer Res 42, 125 (2023) https://doi.org/10.1186/s13046-023-02699-w Following the publication of the original article [1], the authors identified errors in the body. Under the Results, the last paragraph of CircZNF215 is considerably increased in iCCA tissues, and high expression of cZNF215 is correlated with metastasis and poor prognosis in iCCA patients section should be corrected
-
LATS1/2 loss promote tumor immune evasion in endometrial cancer through downregulating MHC-I expression J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-21 Qianlan Yang, Zehen Lv, Mengfei Wang, Mengwen Kong, Cheng Zhong, Kun Gao, Xiaoping Wan
LATS1/2 are frequently mutated and down-regulated in endometrial cancer (EC), but the contributions of LATS1/2 in EC progression remains unclear. Impaired antigen presentation due to mutations or downregulation of the major histocompatibility complex class I (MHC-I) has been implicated in tumor immune evasion. Herein, we elucidate the oncogenic role that dysregulation of LATS1/2 in EC leads to immune
-
PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-21 Sabrina Marcazzan, Marcos J. Braz Carvalho, Nghia T. Nguyen, Julia Strangmann, Julia Slotta-Huspenina, Anna Tenditnaya, Markus Tschurtschenthaler, Jonas Rieder, Andrea Proaño-Vasco, Vasilis Ntziachristos, Katja Steiger, Dimitris Gorpas, Michael Quante, Susanne Kossatz
Esophageal cancer is one of the 10 most common cancers worldwide and its incidence is dramatically increasing. Despite some improvements, the current surveillance protocol with white light endoscopy and random untargeted biopsies collection (Seattle protocol) fails to diagnose dysplastic and cancerous lesions in up to 50% of patients. Therefore, new endoscopic imaging technologies in combination with
-
A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-21 Ying Zhang, Zhaoyong Liu, Zhigang Zhong, Yanchen Ji, Huancheng Guo, Weidong Wang, Chuangzhen Chen
Osteosarcoma (OS) is one of most commonly diagnosed bone cancer. Circular RNAs (circRNAs) are a class of highly stable non-coding RNA, the majority of which have not been characterized functionally. The underlying function and molecular mechanisms of circRNAs in OS have not been fully demonstrated. Microarray analysis was performed to identify circRNAs that are differentially-expressed between OS and
-
Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-19 Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Lingying Wu, Ruibao Ren
Immune checkpoint blockade (ICB) is widely considered to exert long-term treatment benefits by activating antitumor immunity. However, many cancer patients show poor clinical responses to ICB due in part to the lack of an immunogenic niche. Focal adhesion kinase (FAK) is frequently amplified and acts as an immune modulator across cancer types. However, evidence illustrates that targeting FAK is most
-
Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-17 Tengda Li, Maowen Huang, Ning Sun, Xiaohui Hua, Ruifan Chen, Qipeng Xie, Shirui Huang, Mengxiang Du, Yazhen Zhao, Qianqian Lin, Jiheng Xu, Xiaoyun Han, Yunping Zhao, Zhongxian Tian, Yu Zhang, Wei Chen, Xian Shen, Chuanshu Huang
Phosphatase and tensin homolog deleted on chromosome ten (PTEN) serves as a powerful tumor suppressor, and has been found to be downregulated in human bladder cancer (BC) tissues. Despite this observation, the mechanisms contributing to PTEN’s downregulation have remained elusive. We established targeted genes’ knockdown or overexpressed cell lines to explore the mechanism how it drove the malignant
-
The synergism of SMC1A cohesin gene silencing and bevacizumab against colorectal cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-16 Maddalena Di Nardo, Simonetta Astigiano, Silvia Baldari, Maria Michela Pallotta, Giovanni Porta, Simona Pigozzi, Annalisa Antonini, Laura Emionite, Annalisa Frattini, Roberto Valli, Gabriele Toietta, Silvia Soddu, Antonio Musio
SMC1A is a subunit of the cohesin complex that participates in many DNA- and chromosome-related biological processes. Previous studies have established that SMC1A is involved in cancer development and in particular, is overexpressed in chromosomally unstable human colorectal cancer (CRC). This study aimed to investigate whether SMC1A could serve as a therapeutic target for CRC. At first, we studied
-
Retraction Note: MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ ERK signaling pathways J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-15 Ruitao Zhang, Huirong Shi, Fang Ren, Wei Feng, Yuan Cao, Gailing Li, Zheying Liu, Pengcheng Ji, Minghui Zhang
Retraction Note: J Exp Clin Cancer Res 38, 494 (2019) https://doi.org/10.1186/s13046-019-1494-3 The Editor-in-Chief has retracted this article after concerns were raised about some of the data reported. Specifically: In Fig. 3B, the Con and Met + miR-338-3p images for OVCAR3 cells appear to be duplicates. In Fig. 4A, there appears to be partial overlap between the images of MACC1 and Met conditions
-
From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-12 Moksada Regmi, Yingjie Wang, Weihai Liu, Yuwei Dai, Shikun Liu, Ke Ma, Guozhong Lin, Jun Yang, Hongyi Liu, Jian Wu, Chenlong Yang
In tumor therapeutics, the transition from conventional cytotoxic drugs to targeted molecular therapies, such as those targeting receptor tyrosine kinases, has been pivotal. Despite this progress, the clinical outcomes have remained modest, with glioblastoma patients' median survival stagnating at less than 15 months. This underscores the urgent need for more specialized treatment strategies. Our review
-
IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-12 Kaifan Yang, Yanjun Hu, Yuanyuan Feng, Kaiqun Li, Ziyan Zhu, Shuyi Liu, Yanling Lin, Bin Yu
Nasopharyngeal carcinoma (NPC) poses a significant health burden in specific regions of Asia, and some of NPC patients have bone metastases at the time of initial diagnosis. Bone metastasis can cause pathologic fractures and pain, reducing patients' quality of life, and is associated with worse survival. This study aims to unravel the complex role of insulin-like growth factor 1 receptor (IGF-1R) in
-
RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-08 Yu-Jiao Zhou, Min-Li Yang, Xin He, Hui-Ying Gu, Ji-Hua Ren, Sheng-Tao Cheng, Zhou Fu, Zhen-Zhen Zhang, Juan Chen
Metastasis is one of the leading cause contributes to treatment failure and poor prognosis of hepatocellular carcinoma (HCC) patients. The underlying mechanism of HCC metastasis remains to be determined. Although several RNA binding proteins (RBPs) have been found to participate in tumorigenesis and progression of liver cancer, the role of RBPs in HCC patients with extrahepatic metastases is poorly
-
The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-07 Ke Chen, Jingcheng Zhang, Lei Meng, Lingshang Kong, Ming Lu, Zhengguang Wang, Wenbin Wang
m6A modification is currently recognized as a major driver of RNA function that maintains cancer cell homeostasis. Long non-coding (Lnc) RNAs control cell proliferation and play an important role in the occurrence and progression of colorectal cancer (CRC). ZCCHC4 is a newly discovered m6A methyltransferase whose role and mechanism in tumors have not yet been elucidated. The EpiQuik m6A RNA methylation
-
Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-06 Adrien Krug, Marie Tosolini, Blandine Madji Hounoum, Jean-Jacques Fournié, Roger Geiger, Matteo Pecoraro, Patrick Emond, Philippe Gaulard, François Lemonnier, Jean-Ehrland Ricci, Els Verhoeyen
Angioimmunoblastic T-cell lymphoma (AITL) is a malignancy with very poor survival outcome, in urgent need of more specific therapeutic strategies. The drivers of malignancy in this disease are CD4+ follicular helper T cells (Tfh). The metabolism of these malignant Tfh cells was not yet elucidated. Therefore, we decided to identify their metabolic requirements with the objective to propose a novel therapeutic
-
PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-06 Junyu Wu, Hor-Yue Tan, Yau-Tuen Chan, Yuanjun Lu, Zixin Feng, Hongchao Yuan, Cheng Zhang, Yibin Feng, Ning Wang
Par-3 Family Cell Polarity Regulator (PARD3) is a cellular protein essential for asymmetric cell division and polarized growth. This study aimed to study the role of PARD3 in hepatic tumorigenesis. The essential role of PARD3 in mediating hepatic tumorigenesis was assessed in diet-induced spontaneous liver tumour and syngeneic tumour models. The mechanism of PARD3 was delineated by bulk and single-cell
-
Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-06 Giorgia Scafetta, Calogero D’Alessandria, Armando Bartolazzi
Immunotherapy with checkpoint inhibitors (ICIs) has radically changed the landscape of therapeutic opportunities in oncology, but much still needs to be understood from a mechanistic point of view. There is space for further improving tumors’ response to ICIs, as supported by a strong biological rationale. For this achievement a detailed analysis of tumor cell phenotype with functional dissection of
-
Correction: c-Myc-activated long non-coding RNA LINC01050 promotes gastric cancer growth and metastasis by sponging miR-7161-3p to regulate SPZ1 expression J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-05 Ziwei Ji, Tianbin Tang, Mengxia Chen, Buyuan Dong, Wenjing Sun, Nan Wu, Hao Chen, Qian Feng, Xingyi Yang, Rong Jin, Lei Jiang
Correction: J Exp Clin Cancer Res 40, 351 (2021) https://doi.org/10.1186/s13046-021-02155-7 Following the publication of the original article [1], the authors identified a minor error in image-typesetting in Fig. 5a; specifically, the lower panels in Fig. 5a, the incorrect representative image used for invasion transwell assays of KATO III cells transfected with si-LINC01050#1. Fig. 5 LINC01050 knockdown
-
TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-02 Yike Chen, Xiaohui Xu, Kaikai Ding, Tianchi Tang, Feng Cai, Haocheng Zhang, Zihang Chen, Yangjian Qi, Zaixiang Fu, Ganggui Zhu, Zhangqi Dou, Jinfang Xu, Gao Chen, Qun Wu, Jianxiong Ji, Jianmin Zhang
Ubiquitination plays an important role in proliferating and invasive characteristic of glioblastoma (GBM), similar to many other cancers. Tripartite motif 25 (TRIM25) is a member of the TRIM family of proteins, which are involved in tumorigenesis through substrate ubiquitination. Difference in TRIM25 expression levels between nonneoplastic brain tissue samples and primary glioma samples was demonstrated
-
T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-02 Wenhui Yang, Shimao Liu, Mengyun Mao, Yandong Gong, Xiaohui Li, Tianyu Lei, Chao Liu, Shikai Wu, Qinyong Hu
Tumor-infiltrating T cells recognize, attack, and clear tumor cells, playing a central role in antitumor immune response. However, certain immune cells can impair this response and help tumor immune escape. Therefore, exploring the factors that influence T-cell infiltration is crucial to understand tumor immunity and improve therapeutic effect of cancer immunotherapy. The use of single-cell RNA sequencing
-
Correction: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-02-02 Ying Lin, Yun Wu, Qiangzu Zhang, Xunwei Tu, Sufang Chen, Junfan Pan, Nengluan Xu, Ming Lin, Peiwei She, Gang Niu, Yusheng Chen, Hongru Li
Correction: J Exp Clin Cancer Res 43, 1 (2024) https://doi.org/10.1186/s13046-023-02874-z Following publication of the original article [1], the authors spotted an error in the author list. Ying Lin, Yun Wu and Qiangzu Zhang should be captured as equal contributors. The correction does not affect the overall result or conclusion of the article. The original article has been corrected. Lin Y, Wu Y,
-
Lactylation stabilizes DCBLD1 activating the pentose phosphate pathway to promote cervical cancer progression J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-31 Qingfei Meng, Huihui Sun, Yanghe Zhang, Xiangzhe Yang, Shiming Hao, Bin Liu, Honglan Zhou, Zhi-Xiang Xu, Yishu Wang
Discoidin, CUB, and LCCL domain-containing type I (DCBLD1) is identified as an oncogene involved in multiple regulation of tumor progression, but specific mechanisms remain unclear in cervical cancer. Lactate-mediated lactylation modulates protein function. Whether DCBLD1 can be modified by lactylation and the function of DCBLD1 lactylation are unknown. Therefore, this study aims to investigate the
-
EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-29 Mingang Pan, Muyu Luo, Lele Liu, Yunmeng Chen, Ziyi Cheng, Kai Wang, Luyi Huang, Ni Tang, Jianguo Qiu, Ailong Huang, Jie Xia
Hepatocellular Carcinoma (HCC) is a matter of great global public health importance; however, its current therapeutic effectiveness is deemed inadequate, and the range of therapeutic targets is limited. The aim of this study was to identify early growth response 1 (EGR1) as a transcription factor target in HCC and to explore its role and assess the potential of gene therapy utilizing EGR1 for the management
-
FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-29 Zhiyuan Zhou, Bin Zhang, Yue Deng, Suke Deng, Jie Li, Wenwen Wei, Yijun Wang, Jiacheng Wang, Zishan Feng, Mengjie Che, Xiao Yang, Jingshu Meng, Yan Li, Yan Hu, Yajie Sun, Lu Wen, Fang Huang, Yuhan Sheng, Chao Wan, Kunyu Yang
The development of radioresistance seriously hinders the efficacy of radiotherapy in lung cancer. However, the underlying mechanisms by which radioresistance occurs are still incompletely understood. The N6-Methyladenosine (m6A) modification of RNA is involved in cancer progression, but its role in lung cancer radioresistance remains elusive. This study aimed to identify m6A regulators involved in
-
Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-27 Sonia Alcalá, Lara Villarino, Laura Ruiz-Cañas, José R. Couceiro, Miguel Martínez-Calvo, Adrián Palencia-Campos, Diego Navarro, Pablo Cabezas-Sainz, Iker Rodriguez-Arabaolaza, Alfonso Cordero-Barreal, Lucia Trilla-Fuertes, Juan A. Rubiolo, Sandra Batres-Ramos, Mireia Vallespinos, Cristina González-Páramos, Jéssica Rodríguez, Angelo Gámez-Pozo, Juan Ángel Fresno Vara, Sara Fra Fernández, Amparo Benito
Previous studies by our group have shown that oxidative phosphorylation (OXPHOS) is the main pathway by which pancreatic cancer stem cells (CSCs) meet their energetic requirements; therefore, OXPHOS represents an Achille’s heel of these highly tumorigenic cells. Unfortunately, therapies that target OXPHOS in CSCs are lacking. The safety and anti-CSC activity of a ruthenium complex featuring bipyridine
-
MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-25 Shanshan Yu, Cheng Chen, Ming Chen, Jinxiao Liang, Kecheng Jiang, Bin Lou, Jun Lu, Xiaohua Zhu, Donghui Zhou
Gastric cancer (GC) is associated with high mortality and heterogeneity and poses a great threat to humans. Gene therapies for the receptor tyrosine kinase RON and its spliceosomes are attracting increasing amounts of attention due to their unique characteristics. However, little is known about the mechanism involved in the formation of the RON mRNA alternative spliceosome RONΔ160. Fourteen human GC
-
A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-24 Rubén A. Bartolomé, Laura Pintado-Berninches, Ángela Martín-Regalado, Javier Robles, Tania Calvo-López, Marina Ortega-Zapero, Celia Llorente-Sáez, Issam Boukich, María Jesús Fernandez-Aceñero, J. Ignacio Casal
Cadherin-17 (CDH17), a marker of differentiation in intestinal cells, binds and activates α2β1 integrin to promote cell adhesion and proliferation in colorectal cancer (CRC) metastasis. Furthermore, CDH17 associates with p120- and β-catenin in a manner yet to be fully elucidated. In this report, we explored the molecular mediators involved in this association, their contribution to CRC dissemination
-
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-23 Francisco Meraz-Torres, Heike Niessner, Sarah Plöger, Simon Riel, Barbara Schörg, Nicolas Casadei, Manfred Kneilling, Martin Schaller, Lukas Flatz, Boris Macek, Thomas Eigentler, Olaf Rieß, Claus Garbe, Teresa Amaral, Tobias Sinnberg
MEK inhibitors (MEKi) were shown to be clinically insufficiently effective in patients suffering from BRAF wild-type (BRAF WT) melanoma, even if the MAPK pathway was constitutively activated due to mutations in NRAS or NF-1. Thus, novel combinations are needed to increase the efficacy and duration of response to MEKi in BRAF WT melanoma. Disulfiram and its metabolite diethyldithiocarbamate are known
-
HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-23 Haibing Xiao, Yan Qu, Haolin Li, Yi Zhang, Mintian Fei, Chaozhao Liang, Hongmei Yang, Xiaoping Zhang
The VHL-HIF pathway and lipid droplet accumulation are the main characteristics of clear cell renal cell carcinoma (ccRCC). However, the connection between the two features is largely unknown. We used transcriptional sequencing and TCGA database analysis to identify APOL1 as a novel therapeutic target for ccRCC. The oncogenic functions of APOL1 were investigated by cell proliferation, colony formation
-
Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-23 Jie Li, Bin Zhang, Zishan Feng, Dandan An, Zhiyuan Zhou, Chao Wan, Yan Hu, Yajie Sun, Yijun Wang, Xixi Liu, Wenwen Wei, Xiao Yang, Jingshu Meng, Mengjie Che, Yuhan Sheng, Bian Wu, Lu Wen, Fang Huang, Yan Li, Kunyu Yang
Glioblastoma (GBM) is the most common malignant tumor of the central nervous system. It is an aggressive tumor characterized by rapid proliferation, diffuse tumor morphology, and poor prognosis. Unfortunately, current treatments, such as surgery, radiotherapy, and chemotherapy, are unable to achieve good outcomes. Therefore, there is an urgent need to explore new treatment targets. A detailed mechanistic
-
HDAC1/2 control mesothelium/ovarian cancer adhesive interactions impacting on Talin-1-α5β1-integrin-mediated actin cytoskeleton and extracellular matrix protein remodeling J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-23 Michela Terri, Pilar Sandoval, Giulio Bontempi, Claudia Montaldo, Henar Tomero-Sanz, Valeria de Turris, Flavia Trionfetti, Lucía Pascual-Antón, Irene Clares-Pedrero, Cecilia Battistelli, Sergio Valente, Clemens Zwergel, Antonello Mai, Laura Rosanò, Miguel Ángel del Pozo, Miguel Sánchez-Álvarez, Carlos Cabañas, Marco Tripodi, Manuel López-Cabrera, Raffaele Strippoli
Peritoneal metastasis, which accounts for 85% of all epithelial ovarian carcinoma (EOC) metastases, is a multistep process that requires the establishment of adhesive interactions between cancer cells and the peritoneal membrane. Interrelations between EOC and the mesothelial stroma are critical to facilitate the metastatic process. No data is available so far on the impact of histone acetylation/deacetylation
-
Correction: METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-22 Wei Wei, Zhong-Yuan Zhang, Bin Shi, Yike Cai, Hou-Shun Zhang, Chun-Lei Sun, Yun-Fei Fei, Wen Zhong, Shuang Zhang, Chen Wang, Bing He, Guan-Min Jiang, Hao Wang
Correction: J Exp Clin Cancer Res 42, 151 (2023) https://doi.org/10.1186/s13046-023-02732-y Following publication of the original article [1], the authors would spotted errors in the affiliations. ‘The First Affiliated Hospital of USTC’ should come before the division. Affiliations 1, 3, 4, and 6 were corrected accordingly. The corrections do not affect the overall result or conclusion of the article
-
The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-22 Zhiyi Xue, Yan Zhang, Ruiqi Zhao, Xiaofei Liu, Konrad Grützmann, Barbara Klink, Xun Zhang, Shuai Wang, Wenbo Zhao, Yanfei Sun, Mingzhi Han, Xu Wang, Yaotian Hu, Xuemeng Liu, Ning Yang, Chen Qiu, Wenjie Li, Bin Huang, Xingang Li, Rolf Bjerkvig, Jian Wang, Wenjing Zhou
Extensive local invasion of glioblastoma (GBM) cells within the central nervous system (CNS) is one factor that severely limits current treatments. The aim of this study was to uncover genes involved in the invasion process, which could also serve as therapeutic targets. For the isolation of invasive GBM cells from non-invasive cells, we used a three-dimensional organotypic co-culture system where
-
High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor J. Exp. Clin. Cancer Res. (IF 11.3) Pub Date : 2024-01-20 Fangming Wang, Gang Zhang, Tianli Xu, Jianlin Ma, Jing Wang, Shuai Liu, Yuzhe Tang, Song Jin, Jianxing Li, Nianzeng Xing
Non-muscle-invasive bladder cancer (NMIBC) is treated with transurethral resection of bladder tumor (TURBT) followed by intravesical instillation of chemotherapy or Bacillus Calmette–Guérin therapy. However, these treatments have a high recurrence rate and side effects, emphasizing the need for alternative instillations. Previously, we revealed that expanded allogeneic human natural killer (NK) cells